The Coupon That Helps the Patient and Not Their Deductible
Manufacturers offer copay assistance to reduce what patients pay for expensive drugs. Insurers responded with programmes that accept the money without counting it toward the patient own out of pocket limit.
The Instrument and Its Purpose
A high cost specialty drug can carry patient cost sharing of hundreds or thousands of dollars per month. Manufacturers offer copay assistance, typically a card covering most or all of the patient share up to an annual limit.
The stated purpose is access, and it is genuine. A patient who cannot afford the cost share does not fill the prescription, and non adherence to a prescribed treatment produces worse outcomes.
The commercial purpose is also genuine. Cost sharing exists partly to make patients sensitive to price, and assistance removes that sensitivity, which keeps the patient on the branded product rather than switching to a cheaper alternative.
Both descriptions are accurate simultaneously, which is why the practice is contested.
How the Payments Used to Work
Under ordinary plan design, every dollar a patient pays toward cost sharing counts toward the deductible and the out of pocket maximum. Once the maximum is reached, the plan covers everything for the rest of the year.
Historically manufacturer assistance counted the same way. The manufacturer paid, the payment was applied to the patient accumulator, and the patient reached their maximum sooner.
From the plan perspective that was unwelcome. The patient reached the point of full coverage using somebody else money, and the plan bore the remaining cost for the year.
| Assistance Counts | Accumulator Programme | |
|---|---|---|
| Manufacturer pays cost share | Yes | Yes |
| Applied to patient deductible | Yes | No |
| Patient reaches out of pocket maximum | Sooner | Only after paying it themselves |
| Who bears more cost | The plan | The patient and the manufacturer |
The plan accepts the manufacturer money and does not credit it to the patient. The patient discovers this at the moment the annual assistance limit is exhausted and the full cost share arrives with the deductible still unsatisfied.
The Two Variants
A copay accumulator accepts the assistance and does not apply it to the patient accumulators. When the manufacturer annual limit is exhausted, the patient faces the remaining deductible in full.
A copay maximiser goes further. It adjusts the patient cost share for the specific drug to match the maximum available manufacturer assistance, extracting the full annual amount, and spreads it across the year. The drug is frequently designated as non essential health benefit so that the payments need not count toward the out of pocket maximum.
The maximiser is more efficient at capturing the manufacturer money and produces a smoother patient experience, since the assistance is stretched rather than exhausted abruptly.
The Arguments
Plans and pharmacy benefit managers argue that copay assistance undermines the purpose of cost sharing, steering patients toward expensive branded drugs when a generic or biosimilar is available, and that manufacturer assistance is a marketing expense funded by the high list prices plans are being asked to pay. Refusing to credit it restores the incentive the plan designed.
Manufacturers and patient groups argue that the programmes take money intended for the patient and apply it to the plan benefit, that patients are not told clearly, and that the practical effect is patients abandoning necessary treatment when assistance runs out.
The evidence on abandonment is the strongest part of the patient side argument. Studies of prescription abandonment show a strong relationship between out of pocket cost at the pharmacy counter and whether the prescription is collected, with abandonment rising steeply above modest thresholds.
The Legal Position
The regulatory treatment has been unstable.
A federal rule permitted plans to exclude manufacturer assistance from accumulators. A subsequent rule narrowed that to situations where a generic equivalent was available. A later rule broadened it again, and litigation followed.
A federal court in 2023 vacated the broader rule, and the resulting enforcement position has been described by regulators as one of non enforcement pending further rulemaking, which leaves the position genuinely unclear.
Meanwhile a substantial number of states have enacted laws requiring plans to count third party assistance toward patient cost sharing, at least where no generic alternative exists. Those laws generally do not reach self funded employer plans, which are governed by federal law and cover a large share of the insured population.
The practical result is that whether assistance counts depends on the state and on whether the employer plan is insured or self funded, which is not a distinction most patients know about their own coverage.
What a Patient Can Actually Do
The useful steps are narrow. Check whether the plan operates an accumulator or maximiser programme, which is disclosed in plan documents and is rarely prominent. Track how much manufacturer assistance remains and when it will be exhausted, since that is the date the cost arrives. Ask whether a manufacturer patient assistance programme, which is different from copay assistance and is based on income, is available. And understand whether the plan is self funded, since that determines whether state protections apply.
The Bottom Line
Copay accumulators let a plan accept manufacturer assistance without crediting it to the patient deductible, which shifts cost back onto the patient at the point the assistance runs out. Both sides of the argument are substantive: assistance genuinely does blunt the incentive cost sharing was meant to create, and abandonment of prescribed treatment when costs spike is a documented consequence. The regulatory position is unsettled and varies by state and by plan type, which means the answer to whether your assistance counts depends on facts about your coverage that were never explained to you.